基本信息
浏览量:2
职业迁徙
个人简介
His current research focuses on the identification and characterization of the key negative regulators, tumor suppressor proteins, of cancer development and progression, and the development of small molecule-based therapies that activate tumor suppressor genes for the treatment of cancer. To date, Dr. Narla has authored 11 patents. He has over 73 publications in journals including Nature Genetics, Science, Science Translational Medicine, Proceedings of the National Academy of Sciences, and the Journal of Clinical Investigation. His research focuses on understanding the mechanisms driving human cancer development and progression and has led to: 1) the identification of a new class of tumor suppressor genes in human cancer (the Kruppel-like factor family of genes), 2) the characterization of novel mechanisms of tumor suppressor gene inactivation in cancer progression (alternative splicing into dominant negative oncogenic splice variants), 3) the development and validation of pharmaceutically tractable strategies to reactive tumor suppressor gene function for the treatment of a broad range of human cancers, and 4) the structural, functional and biological mechanisms of PP2A inactivation in human cancer. These studies span the continuum of biomedical research starting from fundamental mechanism-driven laboratory-based studies directed at identifying novel cancer genes to the translation of these findings into the development of new drugs for cancer treatment. These novel small-molecule tumor suppressor gene activators represent the first, to our knowledge, example of drugs that directly bind and activate tumor suppressor genes for cancer treatment and provide the mechanistic and translational framework/foundation to develop entire classes of drugs directed at the key negative regulators of oncogenic signaling, an area that to date has not been the focus of major drug development efforts. He is currently the PI on two multi-PI R01 grant applications and three other NIH and DOD awards highlighting the collaborative and multi-disciplinary nature of his work. This work has also led to the formation of RAPPTA Therapeutics, a biotechnology company, seeking to develop these small molecule PP2A modulators for the treatment of cancer.
研究兴趣
论文共 245 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Vidhi Shah, Alexander Smith, Gabriel Cohn,Motoyuki Tsuda,Goutham Narla,Jonathan Brody,Brett Sheppard,Rosalie Sears
CANCER RESEARCHno. 2 (2024)
Sudeh Izadmehr, Heriberto Fernandez-Hernandez,Danica Wiredja,Alexander Kirschenbaum,Christine Lee-Poturalski,Peyman Tavassoli,Shen Yao,Daniela Schlatzer, Divya Hoon,Analisa Difeo,Alice C Levine, Juan-Miguel Mosquera,
bioRxiv : the preprint server for biology (2024)
Analisa DiFeo, Fei Huang,Jaya Sangodkar, Esteban A. Terzo, Devin Leake,Goutham Narla,John A. Martignetti
crossref(2023)
Analisa DiFeo, Fei Huang,Jaya Sangodkar, Esteban A. Terzo, Devin Leake,Goutham Narla,John A. Martignetti
crossref(2023)
Biochimica et biophysica acta. Reviews on cancerno. 5 (2023): 188953-188953
Rita A. Avelar,Amy J. Armstrong, Gracie Carvette, Riya Gupta,Noah Puleo, Jose A. Colina,Peronne Joseph, Alexander M. Sobeck,Caitlin M. O'Connor, Brynne Raines, Agharnan Gandhi,Michele L. Dziubinski,
biorxiv(2023)
Kimberly McClinch,Rita A. Avelar,David Callejas,Sudeh Izadmehr,Danica Wiredja,Abbey Perl,Jaya Sangodkar, David B. Kastrinsky,Daniela Schlatzer,Maxwell Cooper,Janna Kiselar, Agnes Stachnik,
crossref(2023)
Reyaz ur Rasool,Caitlin M. O’Connor, Chandan Kanta Das,Mohammed Alhusayan,Brijesh Kumar Verma,Sehbanul Islam,Ingrid E. Frohner,Qu Deng,Erick Mitchell-Velasquez,Jaya Sangodkar,Aqila Ahmed, Sarah Linauer,
引用0浏览0WOSNATURE引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn